(S1 (S (S (NP (NP (NN IKK) (NN beta) (NN suppression)) (PP (IN of) (NP (NN TSC1)))) (VP (VBZ links) (NP (NP (NN inflammation)) (CC and) (NP (NN tumor) (NN angiogenesis))) (PP (IN via) (NP (DT the) (NN mTOR) (NN pathway))))) (. .)))
(S1 (S (S (S (NP (NN TNFalpha)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN emerged) (PP (IN as) (NP (NP (DT a) (NN regulator)) (VP (VBG linking) (NP (NN inflammation)) (PP (TO to) (NP (NN cancer) (NN pathogenesis))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ detailed) (ADJP (ADJP (JJ cellular)) (CC and) (ADJP (JJ molecular))) (NNS mechanisms)) (VP (VBG underlying) (NP (DT this) (NN link)))) (VP (VBP remain) (S (VP (TO to) (VP (VB be) (VP (VBN elucidated)))))))) (. .)))
(S1 (S (S (S (NP (DT The) (NN tuberous) (NN sclerosis) (CD 1) (-LRB- -LRB-) (NN TSC1) (-RRB- -RRB-) (NN /TSC2) (NN tumor) (NN suppressor) (NN complex)) (VP (VBZ serves) (PP (IN as) (NP (NP (DT a) (NN repressor)) (PP (IN of) (NP (DT the) (NN mTOR) (NN pathway))))))) (, ,) (CC and) (S (NP (NP (NN disruption)) (PP (IN of) (NP (NN TSC1/TSC2) (NN complex) (NN function)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NN tumorigenesis))))))) (. .)))
(S1 (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN IKKbeta)) (, ,) (NP (NP (DT a) (JJ major) (JJ downstream) (NN kinase)) (PP (IN in) (NP (DT the) (NN TNFalpha) (NN signaling) (NN pathway)))) (, ,)) (ADVP (RB physically)) (VP (VP (VBZ interacts) (PP (IN with))) (CC and) (VP (VBZ phosphorylates) (NP (NN TSC1)) (PP (IN at) (NP (NP (NN Ser487)) (CC and) (NP (NN Ser511)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN suppression)) (PP (IN of) (NP (NN TSC1)))))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ IKKbeta-mediated) (NN TSC1) (NN suppression)) (VP (VP (VBZ activates) (NP (DT the) (NN mTOR) (NN pathway))) (, ,) (VP (VBZ enhances) (NP (NN angiogenesis))) (, ,) (CC and) (VP (VBZ results) (PP (IN in) (NP (NN tumor) (NN development)))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB further)) (VP (VBP find) (SBAR (IN that) (S (NP (NP (NN expression)) (PP (IN of) (NP (VBN activated) (NN IKKbeta)))) (VP (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (NN TSC1) (NN Ser511) (NN phosphorylation)) (CC and) (NP (NN VEGF) (NN production))) (PP (IN in) (NP (JJ multiple) (NN tumor) (NNS types))))))) (CC and) (VP (VBZ correlates) (PP (IN with) (NP (NP (JJ poor) (JJ clinical) (NN outcome)) (PP (IN of) (NP (NN breast) (NN cancer) (NNS patients))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS findings)) (VP (VBP identify) (NP (NP (DT a) (NN pathway)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (JJ inflammation-mediated) (NN tumor) (NN angiogenesis))))) (CC and) (VP (MD may) (VP (VB provide) (NP (NP (DT a) (NN target)) (PP (IN for) (NP (NP (JJ clinical) (NN intervention)) (PP (IN in) (NP (JJ human) (NN cancer)))))))))))))) (. .)))
